157 related articles for article (PubMed ID: 27612501)
1. Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial.
Tanamas SK; Saulnier PJ; Fufaa GD; Wheelock KM; Weil EJ; Hanson RL; Knowler WC; Bennett PH; Nelson RG
Diabetes Care; 2016 Nov; 39(11):2004-2010. PubMed ID: 27612501
[TBL] [Abstract][Full Text] [Related]
2. Structural Predictors of Loss of Renal Function in American Indians with Type 2 Diabetes.
Fufaa GD; Weil EJ; Lemley KV; Knowler WC; Brosius FC; Yee B; Mauer M; Nelson RG
Clin J Am Soc Nephrol; 2016 Feb; 11(2):254-61. PubMed ID: 26792530
[TBL] [Abstract][Full Text] [Related]
3. Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes.
Looker HC; Mauer M; Saulnier PJ; Harder JL; Nair V; Boustany-Kari CM; Guarnieri P; Hill J; Esplin CA; Kretzler M; Nelson RG; Najafian B
J Am Soc Nephrol; 2019 Jun; 30(6):1049-1059. PubMed ID: 31152118
[TBL] [Abstract][Full Text] [Related]
4. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes.
Weil EJ; Fufaa G; Jones LI; Lovato T; Lemley KV; Hanson RL; Knowler WC; Bennett PH; Yee B; Myers BD; Nelson RG
Diabetes; 2013 Sep; 62(9):3224-31. PubMed ID: 23545707
[TBL] [Abstract][Full Text] [Related]
5. Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes.
Saulnier PJ; Wheelock KM; Howell S; Weil EJ; Tanamas SK; Knowler WC; Lemley KV; Mauer M; Yee B; Nelson RG; Beisswenger PJ
Diabetes; 2016 Dec; 65(12):3744-3753. PubMed ID: 27609106
[TBL] [Abstract][Full Text] [Related]
6. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
[TBL] [Abstract][Full Text] [Related]
7. Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes.
Saulnier PJ; Dieter BP; Tanamas SK; McPherson SM; Wheelock KM; Knowler WC; Looker HC; Meek RL; Nelson RG; Tuttle KR
Am J Nephrol; 2017; 46(4):276-284. PubMed ID: 28934744
[TBL] [Abstract][Full Text] [Related]
8. Serum Level of Polyubiquitinated PTEN and Loss of Kidney Function in American Indians With Type 2 Diabetes.
Looker HC; Lin C; Nair V; Kretzler M; Mauer M; Najafian B; Nelson RG
Am J Kidney Dis; 2022 Apr; 79(4):497-506. PubMed ID: 34562525
[TBL] [Abstract][Full Text] [Related]
9. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
Kjaergaard KD; Peters CD; Jespersen B; Tietze IN; Madsen JK; Pedersen BB; Novosel MK; Laursen KS; Bibby BM; Strandhave C; Jensen JD
Am J Kidney Dis; 2014 Dec; 64(6):892-901. PubMed ID: 25011693
[TBL] [Abstract][Full Text] [Related]
11. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
12. Evolution of incipient nephropathy in type 2 diabetes mellitus.
Lemley KV; Abdullah I; Myers BD; Meyer TW; Blouch K; Smith WE; Bennett PH; Nelson RG
Kidney Int; 2000 Sep; 58(3):1228-37. PubMed ID: 10972685
[TBL] [Abstract][Full Text] [Related]
13. Urine metabolites are associated with glomerular lesions in type 2 diabetes.
Saulnier PJ; Darshi M; Wheelock KM; Looker HC; Fufaa GD; Knowler WC; Weil EJ; Tanamas SK; Lemley KV; Saito R; Natarajan L; Nelson RG; Sharma K
Metabolomics; 2018 Jun; 14(6):84. PubMed ID: 30830355
[TBL] [Abstract][Full Text] [Related]
14. Early intensive treatment improves outcomes in patients with glomerular hyperfiltration and type 2 diabetes.
Troya MI; Bonet J; Salinas I; Torres F; Bonal J; Sanmartí A; Romero R
Med Clin (Barc); 2016 Jan; 146(2):55-60. PubMed ID: 26343155
[TBL] [Abstract][Full Text] [Related]
15. High Baseline Levels of Tumor Necrosis Factor Receptor 1 Are Associated With Progression of Kidney Disease in Indigenous Australians With Diabetes: The eGFR Follow-up Study.
Barr ELM; Barzi F; Hughes JT; Jerums G; Hoy WE; O'Dea K; Jones GRD; Lawton PD; Brown ADH; Thomas M; Ekinci EI; Sinha A; Cass A; MacIsaac RJ; Maple-Brown LJ
Diabetes Care; 2018 Apr; 41(4):739-747. PubMed ID: 29367427
[TBL] [Abstract][Full Text] [Related]
16. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH
Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246
[TBL] [Abstract][Full Text] [Related]
18. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
19. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Lacourcière Y; Bélanger A; Godin C; Hallé JP; Ross S; Wright N; Marion J
Kidney Int; 2000 Aug; 58(2):762-9. PubMed ID: 10916100
[TBL] [Abstract][Full Text] [Related]
20. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
